On Dec. 18, Curis, Inc. (NASDAQ:CRIS) announced that the first patient has initiated treatment with CUDC-907 in a Phase 1 clinical trial in patients with advanced or relapsed solid tumors, including hormone receptor positive (HR+)/ HER2-negative breast cancer or midline carcinoma with certain NUT gene rearrangements. CUDC-907 is an oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is currently under … Continue reading Why Trader’s Are Watching: Curis, Inc. (NASDAQ:CRIS), BlackBerry Ltd (NASDAQ:BBRY), Goldfield Corp. (NYSEMKT:GV), Entergy Corporation (NYSE:ETR), Las Vegas Sands Corp. (NYSE:LVS)